Neurotech International Ltd has released a press release.
NTI Receives HREC/TGA Approval for Phase II/III ASD Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- Neurotech Receives $1.2M R&D Tax Rebate
- Reinstatement to Quotation
- Neurotech Completes $9.0M Placement
- Suspension From Official Quotation
- 20 Week Data Shows Significant Improvement For ASD Children
Later from Neurotech International
- Commencement of Phase II/III ASD Clinical Trial
- Disclosure Document
- NTI Granted FDA Pre-IND Meeting for NTI164 in ASD
- HREC Approval for Phase I/II PANDAS/PANS Clinical Trial
- Approval for Additional Phase I/II ASD Trial Extension
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International